RNA
insider transactionsAtrium Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Chief Corporate Affairs Offic…
$0
60.0K sh
Own New
-
Grant·A
Chief Corporate Affairs Offic…
$0
30.0K sh
Own +549%
-
Grant·A
Chief Medical Officer
$0
60.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
30.0K sh
Own +70%
-
Grant·A
Chief Financial Officer
$0
60.0K sh
Own New
-
Grant·A
Chief Financial Officer
$0
30.0K sh
Own +221%
-
Grant·A
Chief Executive Officer and P…
$0
205.0K sh
Own New
-
Grant·A
Chief Executive Officer and P…
$0
102.5K sh
Own +355%
-
Grant·A
Chief Strategy Officer
$0
60.0K sh
Own New
-
Grant·A
Chief Strategy Officer
$0
30.0K sh
Own +180%
-
Grant·A
Chief Scientific Officer
$0
60.0K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
30.0K sh
Own +132%
-
Grant·A
Director
$0
20.0K sh
Own New
-
Grant·A
Director
$0
20.0K sh
Own New
-
Grant·A
Director
$0
20.0K sh
Own New
-
Grant·A
Director
$0
20.0K sh
Own New
-
Grant·A
Director
$0
20.0K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Apr 20, 2026 | Stephanie Kenney | Grant A | 60.0K | $0 |
| Apr 20, 2026 | Stephanie Kenney | Grant A | 30.0K | $0 |
| Apr 20, 2026 | Steven George Hughes | Grant A | 60.0K | $0 |
| Apr 20, 2026 | Steven George Hughes | Grant A | 30.0K | $0 |
| Apr 20, 2026 | Brendan R. Winslow KEY | Grant A | 60.0K | $0 |
| Apr 20, 2026 | Brendan R. Winslow KEY | Grant A | 30.0K | $0 |
| Apr 20, 2026 | Kathleen P. Gallagher KEY | Grant A | 205.0K | $0 |
| Apr 20, 2026 | Kathleen P. Gallagher KEY | Grant A | 102.5K | $0 |
| Apr 20, 2026 | Rocio Martin Hoyos | Grant A | 60.0K | $0 |
| Apr 20, 2026 | Rocio Martin Hoyos | Grant A | 30.0K | $0 |
| Apr 20, 2026 | Husam Younis | Grant A | 60.0K | $0 |
| Apr 20, 2026 | Husam Younis | Grant A | 30.0K | $0 |
| Feb 27, 2026 | Sarah Boyce | Grant A | 20.0K | $0 |
| Feb 27, 2026 | Carsten Boess | Grant A | 20.0K | $0 |
| Feb 27, 2026 | Troy Edward Wilson | Grant A | 20.0K | $0 |
| Feb 27, 2026 | Michael W. Flanagan | Grant A | 20.0K | $0 |
| Feb 27, 2026 | Simona Skerjanec | Grant A | 20.0K | $0 |
About RNA insider trading
This page tracks insider transactions for Atrium Therapeutics, Inc. (RNA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.